East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Adalimumab
Adalimumab
Routinely available
NICE (TA373 (SMC 881/13))
04/12/2024

Indication

In combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).

In combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

-

Comments

Refer to pathway or local board guidelines for preferred formulation

Link to Advice

TA373 (SMC 881/13)

Advice Published

16/12/2015